1Q 2024 operating revenue of $42.3 billion, up 0.9% from 1Q 2023 1Q 2024 diluted EPS1 of $9.59, up 15.5% from 1Q 2023 and adjusted diluted EPS2 of $10.64, up 12.5% FY 2024 diluted EPS and adjusted diluted EPS guidance raised to greater than $34.05 and $37.20, respectively Launching strategic partnership to advance primary care and physician enablement INDIANAPOLIS / Apr 18, 2024 / Business Wire / Elevance Health, Inc. (NYSE: ELV)...Read more
Collaboration will leverage the strengths of three care provider entities that will come together to deliver value to consumers and employers across the healthcare journey INDIANAPOLIS / Apr 15, 2024 / Business Wire / Elevance Health, Inc. (NYSE: ELV) and Clayton, Dubilier & Rice (CD&R) announced an agreement to form a strategic partnership to accelerate innovation in primary care delivery, enhance the healthcare experience,...Read more
LONG BEACH, Calif. / Apr 11, 2024 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) (“Molina” or the “Company”) announced today that the Michigan Department of Health and Human Services (MDHHS) intends to award a Comprehensive Health Care Program contract to Molina’s health plan subsidiary, Molina Healthcare of Michigan. Molina confirmed it was awarded the contract in six service regions. The go-live date for Molina Healthcare of...Read more
ST. LOUIS, April 9, 2024 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that its subsidiary, Meridian in Michigan (Meridian), has been selected by the Michigan Department of Health and Human Services (MDHHS) to continue to serve as a Medicaid health plan for the Comprehensive Health Care Program, which serves nearly 2 million...Read more
Full Year Benefit of Maestro Acquisition and Q4 Corrective Actions Driving Financial Improvement TAMPA, Fla., March 26, 2024 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans with affordable, intelligent healthcare, today announced financial...Read more
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE